

Regimen Reference Order – SUPP – ferric derisomaltose

ARIA: HEME - [ferric derisomaltose]

Planned Course: Until iron stores are replete

Indication for Use: Iron deficiency anemia in adult patients

CVAD: At Provider's Discretion

Blood work requirements:

❖ *Blood work at provider's discretion; not required to proceed with treatment*

SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements

Drug	Dose	CCMB Administration Guideline
Not Applicable		

Treatment Regimen – SUPP – ferric derisomaltose

Drug	Dose*	CCMB Administration Guideline
ferric derisomaltose (MONOFERRIC®)	Dose less than 1000 mg	IV in normal saline 100 mL following administration rates below: <ul style="list-style-type: none"> 0 to 10 minutes – 170 mL/hour 10 minutes onwards – 340 mL/hour (Total infusion time approximately 25 minutes)
	Dose equal to or greater than 1000 mg	IV in normal saline 100 mL following administration rates below: <ul style="list-style-type: none"> 0 to 10 minutes – 120 mL/hour 10 minutes onwards – 240 mL/hour (Total infusion time approximately 35 minutes)
*ferric derisomaltose dose and frequency to be determined by prescriber. Refer to Shared Health Parenteral Drug Monograph for usual dose based on hemoglobin and weight		

In the event of an infusion-related hypersensitivity reaction, refer to the 'Hypersensitivity Reaction Standing Order'

REQUIRED MONITORING

All infusions

- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and O₂ saturation) at baseline, at the end of infusion and as clinically indicated
- Observe patient for 30 minutes after ferric derisomaltose infusion. Full vital signs prior to discharge

Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
None required		

DISCHARGE INSTRUCTIONS

- Patients should be instructed to contact their cancer team immediately if symptoms of hypersensitivity reactions occur after discharge

ADDITIONAL INFORMATION

- ferric derisomaltose is also known as iron isomaltoside or MONOFERRIC®
- ferric derisomaltose should be prepared by treatment room nurse immediately prior to administration
- ferric derisomaltose should be administered with caution to avoid paravenous leakage during administration; can lead to irritation of the skin and long-lasting brown discolouration at the injection site. In case of paravenous leakage, the administration must be stopped immediately
- ferric derisomaltose is associated with hypophosphatemia
- Support protocol is available under **[ferric derisomalt]** in the “Hematology” folder